Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3493269 · 4 trials · 2 indications
TEAE is an untoward medical occurrence that emerges during a defined treatment period, having been absent pretreatment, or worsens relative to the pretreatment state, and does not necessarily have to have a causal relationship with this treatment. A summary of serious adverse events (SAEs), TEAEs and other non-serious adverse events (AEs), regardless of causality, were reported in the Adverse Events section of this record.
An SAE is an adverse event that results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
TEAE is an untoward medical occurrence that emerges during a defined treatment period, having been absent pretreatment, or worsens relative to the pretreatment state, and does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence that, at any dose: 1. Results in death 2. Is life-threatening 3. Requires inpatient hospitalization or prolongation of existing hospitalization 4. Results in persistent disability/incapacity 5. Is a congenital anomaly/birth defect 6. Other situations: Based on medical or scientific judgement. A summary of SAEs, TEAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participants received placebo orally once daily (QD) for three consecutive days. |
| 8 Milligrams (mg) LY3493269 + 600 mg Salcaprozate Sodium (SNAC) | EXPERIMENTAL | Participants received 8 mg LY3493269 and 600 mg SNAC QD administered orally for three consecutive days. |
| 24 mg LY3493269 + 600 mg SNAC | EXPERIMENTAL | Participants received 24 mg LY3493269 and 600 mg SNAC QD administered orally for three consecutive days. |
| 12 mg LY3493269 + 300 mg SNAC | EXPERIMENTAL | Participants received 12 mg LY3493269 and 300 mg SNAC QD administered orally for three consecutive days. |
| 4 mg LY3493269 + 300 mg SNAC | EXPERIMENTAL | Participants received 4 mg LY3493269 and 300 mg SNAC QD administered orally for three consecutive days. |
| LY3493269 | EXPERIMENTAL | 8, 24 or 48 milligrams (mg) LY3493269 + 250 or 500 mg permeation enhancer sodium caprate(C10) Once daily (QD) administered orally over 3 consecutive study days. |
| 1.5 milligrams (mg) Dulaglutide | ACTIVE_COMPARATOR | Participants received 1.5 mg dulaglutide subcutaneously (SC) once weekly (QW) for 4 weeks. |
| 0.3 mg LY3493269 | EXPERIMENTAL | Participants received 4 fixed dosed of 0.3 mg LY3493269 SC QW for 4 weeks. |
| 1 mg LY3493269 | EXPERIMENTAL | Participants received 4 fixed dosed of 1 mg LY3493269 SC QW for 4 weeks. |
| 0.75/1.5/3 mg LY3493269 | EXPERIMENTAL | Participants received LY3493269 0.75 mg on week 1, 1.5 mg on week 2 and 3 mg on week 3 and 4 SC as weekly doses. |
| 1.5/3/4/5 mg LY3493269 | EXPERIMENTAL | Participants received LY3493269 1.5 mg on week 1, 3 mg on week 2, 4 mg on week 3 and 5 mg on week 4 as weekly doses. |
| Placebo - SC | PLACEBO_COMPARATOR | Participants received Placebo subcutaneously (SC). |
| 0.5 mg LY3493269 IV | EXPERIMENTAL | Participants received 0.5 mg LY3493269 intravenously (IV). |
| 0.15 mg LY3493269 SC | EXPERIMENTAL | Participants received 0.15 mg LY3493269 SC. |
| 0.5 mg LY3493269 SC | EXPERIMENTAL | Participants received 0.5 mg LY3493269 SC. |
| 1.5 mg LY3493269 SC | EXPERIMENTAL | Participants received 1.5 mg LY3493269 SC. |
| Name | Type | Description |
|---|---|---|
| LY3493269 | DRUG | Administered orally. |
| Placebo | DRUG | Administered orally. |
| Salcaprozate Sodium | DRUG | Administered orally. |
| Dulaglutide | DRUG | Administered SC |
| LY3493269 - SC | DRUG | Administered SC |
| Placebo - SC | DRUG | Administered SC |
| LY3493269 - IV | DRUG | Administered IV |
Inclusion Criteria: 1. Are male or female not of childbearing potential 2. Body mass index within the range of 19.0 to 40.0 kilograms per square meter (kg/m²) (inclusive) 3. Participants who are healthy as determined through medical evaluation including screening medical history, physical examinati...
LY3493269 is an investigational small molecule being studied for Type 2 Diabetes Mellitus and in healthy participants. It is in Phase 1 clinical development by Eli Lilly and Company. The drug is not approved and remains under investigation for metabolic conditions.
LY3493269 is being developed by Eli Lilly and Company, a biopharmaceutical company traded on the stock exchange under the ticker LLY. The company is conducting Phase 1 clinical trials to evaluate the safety and effects of this investigational small molecule.
LY3493269 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. All completed trials for LY3493269 are Phase 1 studies, and the drug is not yet available for clinical use.
LY3493269 has been studied in four completed Phase 1 clinical trials. These include NCT04178733 and NCT04498390 in healthy participants in Singapore, NCT04515576 in participants with Type 2 Diabetes in the United States, and NCT04682106 in healthy participants in Singapore.
LY3493269 is the primary name for this investigational drug. No alternative names have been reported for this compound. It is a small molecule being developed by Eli Lilly and Company for metabolic conditions, and it is not known to be identical to any other marketed medication.